The Door That Opens When You're About to Lose Everything

In a 2022 qualitative study published in the Journal of Substance Abuse Treatment, researchers interviewed 22 parents with opioid use disorder who had eventually entered treatment. The interviews were designed to understand not just what had helped them get help — but what had kept them from it first. The answers were consistent. Shame. Fear of judgment. And, most specifically, something concrete: the belief that disclosing opioid use to a doctor would reach a caseworker, and the caseworker would take their children.

In a significant number of cases, they were right to be afraid.

The administration for Children and Families announced on February 2, 2026 that buprenorphine, methadone, and naltrexone — the three FDA-approved medications for opioid use disorder — are now eligible for Title IV-E funding. That’s the federal funding stream for child welfare prevention services. States and tribes can now receive a 50 percent federal match to provide these medications to parents when their children face “imminent risk of entering foster care but can remain safely in the home or in a kinship placement” with treatment access. The American Academy of Addiction Psychiatry called it “a critical recognition that treating parental OUD is an essential family preservation tool” — a phrase that sounds obvious and is somehow only now official policy.

The policy is real, the funding is real, and it will reach families it couldn’t before. It is also, in its conditions of eligibility, an X-ray of the failure that preceded it.

Shame is not a feeling — it’s a treatment barrier with a documented effect size

When researchers study why people delay seeking treatment for opioid use disorder, they find a cluster of factors that are more specific than “stigma” — the word that gets used as a summary but flattens what’s actually happening. For parents, the cluster has a particular shape.

Shame and guilt are distinct emotions, and addiction medicine researchers have started treating them as such. Guilt is the feeling of having done something wrong. Shame is the feeling of being wrong — being a bad person, an inadequate parent, a threat to the children you’re trying to protect. The evidence on shame in addiction treatment is remarkably consistent: it predicts treatment avoidance, accelerated relapse, and dropout from treatment once started. A 2023 analysis in Addictive Behaviors found that shame proneness in people with OUD was a stronger predictor of treatment dropout than pain severity, co-occurring mental health diagnoses, or social support levels. Shame does not motivate change. It motivates hiding.

For parents, shame takes a form that is structurally reinforced, not just internalized. The system has, for decades, treated parental substance use as a child welfare risk factor first and a treatable medical condition second. The practical consequence: a parent who discloses OUD to an OB-GYN or primary care physician may trigger a mandatory report. A parent on methadone maintenance who is otherwise stable may face custody challenges in family court, where the medication — evidence-based and FDA-approved — is sometimes treated as ongoing drug use rather than treatment. The parents in the Michigan study were not imagining the consequences of disclosure. Many had seen them happen to people they knew.

The University of Michigan researchers found that among the 22 parents they interviewed, parents reported delaying treatment for an average of 18 to 24 months longer than comparable adults without dependent children. Dr. Mishka Terplan, an addiction medicine specialist whose research focuses on pregnant and parenting women with substance use disorders, argued in Obstetrics and Gynecology in 2019 that the gap reflects a category error embedded in American healthcare: “We treat parental substance use disorder as a child welfare problem rather than a medical one. That inversion means the system’s first response is protective custody, not prescribing — and the result is that parents learn that honesty is dangerous.”

That inversion means the system’s first response is protective custody, not prescribing — and the result is that parents learn that honesty is dangerous.”

Eighteen to twenty-four months of untreated OUD, at current fentanyl concentrations in the drug supply, is enough time to die. The ACF expansion doesn’t reach people in that window. It reaches people after it.

The data on what happens when parents do get MOUD

The case for this expansion is empirically strong. Studies looking at parents who received medication-assisted treatment compared to those who received no treatment show dramatically different outcomes on the child welfare metrics that matter to caseworkers and family court judges: rates of family reunification after placement, rates of sustained custody, rates of re-reporting to child protective services.

A 2023 review in Child Abuse and Neglect synthesized 14 studies examining substance use treatment for parents with children in the welfare system. Every study that included MOUD showed statistically significant improvements in family preservation outcomes compared to behavioral-only or no-treatment conditions. Several studies showed that buprenorphine specifically — the medication most accessible through primary care and telehealth — reduced re-reporting rates by 30 to 40 percent when parents maintained adherence.

On the child side, the picture is equally stark. A 2024 cohort study tracking nearly 2 million children with a Medicaid-enrolled parent experiencing OUD found that foster care involvement increased from roughly 2 percent in 2014 to more than 5 percent by 2020 — a tripling in six years, accelerating before and through the pandemic. Those children had significantly higher rates of mental health diagnoses, developmental disorders, and — by early adulthood — their own substance use disorders. The intergenerational math is direct: when parents don’t get treatment, the next generation carries the cost.

The ACF expansion creates a reimbursement mechanism that removes a specific structural barrier clinicians have complained about for years. In contexts where child welfare services were being delivered under Title IV-E, MOUD had no billing home. Caseworkers who wanted to connect families to medication sometimes couldn’t because no one could pay for it under the funding stream they were operating under. That gap is now closed, at least for families at the imminent removal threshold.

What Arizona’s picture actually looks like

Arizona does not make this easy in practice. The AHCCCS SFY2025 annual report puts Arizona 49th out of 51 jurisdictions in behavioral health access. Fewer than 1 in 20 Arizonans with opioid use disorder receive any medication — a gap that reflects prescriber shortages, particularly in rural counties, alongside the cultural barriers the research documents.

The Title IV-E expansion creates a funding mechanism. It does not create prescribers, clinic hours, or transportation to care for families in rural Maricopa County, let alone Navajo County or La Paz. Arizona’s legislature, in the same FY2026 appropriations cycle that landed in April, repealed AHCCCS’s ability to use the hospital assessment to fund behavioral health services for a subset of Medicaid enrollees at the income margins — a change that takes effect July 1, 2026. The federal money flowing through Title IV-E matters. What it flows into is a system under concurrent pressure.

The Arizona Department of Child Safety processed more than 46,000 reports in SFY2025. Parental substance use disorder was a contributing factor in a significant proportion. Those families now have a clearer path to MOUD coverage than they did four months ago. What they need alongside it — transportation, childcare during treatment, peer support, a caseworker who understands that methadone is medicine — is not funded by the expansion.

A 2023 editorial in The Imprint made the argument directly: child welfare systems that refer families to substance use treatment “as a condition of reunification without actually facilitating access are simply adding another requirement to a list of requirements — not removing a barrier.” The ACF expansion is meaningful precisely because it creates a financial mechanism to actually fund the medication, not just require it.

The harder question: what happens before the threshold

The Title IV-E expansion covers families at imminent foster care risk. It does nothing for the parent who is three months before crisis — using opioids, terrified of the system, and not yet in contact with DCS.

It does nothing for the parent who is three months before crisis — using opioids, terrified of the system, and not yet in contact with DCS.

That parent is the harder problem, and there is no federal funding stream designed to reach them. The research suggests the most effective interventions in parental OUD happen in obstetrics — perinatal OUD has received disproportionate attention compared to parental OUD generally, and programs that integrate treatment with prenatal care, without punitive reporting frameworks, consistently show higher treatment uptake. Rhode Island’s Statewide MOUD navigation program and Minnesota’s MOTHER program are among the documented examples.

What doesn’t exist, at scale, is a version of that for the parent with a four-year-old. Or a teenager. There is no federally funded routine screening in pediatric primary care settings with warm handoffs to treatment and recovery navigation. There is no financial mechanism for a family preservation caseworker to connect a parent to buprenorphine before the imminent removal threshold is reached. There is a waiting list.

“The door is finally open,” one addiction medicine physician at a federally qualified health center in Phoenix told Rize, speaking on condition of anonymity because they work directly with DCS-involved families and didn’t want to risk the relationship. “The question is how many people are still afraid to walk through it.”

That fear doesn’t dissipate with a funding announcement. Shame is a systemic output, not an individual character trait. It is produced by systems that have told parents, for decades, that asking for help is the thing that costs them their children. Reversing it requires not just changing the funding rules but changing the experience — repeatedly, case by case — of what happens when a parent tells the truth.

The ACF expansion is, at minimum, the government acknowledging that the treatment works, the family preservation rationale is sound, and the money should follow. For the families it will reach — in the narrowest and most crisis-adjacent slice of opioid use disorder treatment — that matters. What comes before the threshold remains unanswered.